SynthesisUrologie (Heidelberg, Germany)2026
[Tranexamic acid for prevention of bleeding complications-a rational approach? : Results of a systematic literature review and evidence synthesis].
Synthesis in Urologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPerioperative bleeding complications are common adverse events. Tranexamic acid (TXA), through inhibition of fibrinolysis, may contribute to a reduction of such events. However, safety concerns remain, particularly with respect to thromboembolic complications.
objectiveThis study aimed to evaluate whether TXA constitutes a meaningful and safe measure for prevention of bleeding complications. Potential areas of application include perioperative care as well as emergency management. MATERIALS AND
methodsA literature search of the MEDLINE database via PubMed, Google Scholar, and the Cochrane Library was conducted for publications in German and English from 2015 to 2025. The systematic literature search was prospectively registered with PROSPERO (CRD420251162415) and followed the PRISMA guidelines. Reviews and comments were excluded. A total of 32 full-text articles were considered for final analysis.
resultsTranexamic acid has been investigated in transurethral resection of the prostate (TURP), prostatectomy, radical cystectomy, and percutaneous nephrolithotomy (PCNL). Both topical and systemic administration of TXA were associated with a reduction in bleeding complications. Several studies demonstrated a significantly reduced postoperative hemoglobin drop and decreased bleeding volume. In cases of greater blood loss, transfusion rates were also reliably reduced. Catheterization time and hospital stay were largely unchanged. The duration and dosage of TXA administration varied across studies. No increased incidence of thromboembolic events was observed. Since patients with cardiovascular risk factors were frequently excluded, no reliable data are available for this subgroup.
conclusionIn otherwise healthy patient populations, TXA appears to be a safe and effective means of preventing bleeding complications. Further studies are warranted in patients with cardiovascular risk factors before its unrestricted use can be recommended.
Indexed as
Identifiers
41364110What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.